FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

08/21/14 - 20140234295 - Isoflavonoid compounds and methods for the treatment of cancer
Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions....

08/21/14 - 20140234296 - Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
The present invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The present invention further provides methods for treating various cancers and chronic infections with stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof....

08/21/14 - 20140234297 - Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically...

08/21/14 - 20140234298 - Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
The present disclosure describes a pharmaceutical combination of an anti-CD20 antibody and an anti-GM-CSF antibody. Said combinations are highly efficacious in the treatment of B cell malignancies and inflammatory disorders....

08/21/14 - 20140234299 - Therapies for chronic renal failure using one or more integrin antagonists
The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists....

08/21/14 - 20140234300 - Method of modulating the activity of functional immune molecules
The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity....

08/21/14 - 20140234301 - Modulation of pilr to treat immune disorders
The present invention provides methods of using PILRα agonists, or PILRβ antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation....

08/21/14 - 20140234302 - Methods and compositions for reducing amyloid beta levels
The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for...

08/21/14 - 20140234303 - Treatment of neurological conditions
The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the CNS in a subject comprising administering to said subject a G-CSF or G-CSFR inhibiting agent selected from the group consisting of an antibody specific for G-CSF, a soluble G-CSFR or a G-CSF-binding portion thereof...

08/21/14 - 20140234304 - Human tissue factor antibody and uses thereof
The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions,...

08/21/14 - 20140234305 - Methods of treatment using bevacizumab
Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an...

08/21/14 - 20140234306 - Agent and method for reducing inflammatory markers
A method for treating an autism spectrum condition includes administering an effective dose of a TNF-α inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum, as compared to...

08/21/14 - 20140234307 - Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
Described herein are methods of treating multiple sclerosis (MS), such as secondary progressive MS (SPMS), by intrathecally administering a B cell depleting agent, such as rituximab, alone or in combination with intravenous administration of a B cell depleting agent. Also described is the use of IL-12p40, CXCL13, or both as...

08/21/14 - 20140234308 - Treatment of breast cancer with companion diagnostic
Despite advances in therapy, breast cancer remains the most common malignancy in women. Of particular concern is the aggressive triple negative subtype that lacks the BRCA1 mutation, estrogen receptor, and epidermal growth factor type 2 receptor (Her-2/neu), which accounts for approximately half of all breast cancer deaths. Provided herein are...

08/14/14 - 20140227250 - Stable formulations of antibodies to tslp
The present invention relates to stable formulations of antibodies against human TSLP, or antigen binding fragments thereof....

08/14/14 - 20140227251 - Methods for identifying antibodies with reduced immunogenicity
The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti-TNF-α antibody having reduced immunogenicity as compared to the reference anti-TNF-α reference antibody....

08/14/14 - 20140227252 - Methods and monitoring of treatment with a dll4 antagonist
Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity....

08/14/14 - 20140227253 - Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such...

08/14/14 - 20140227254 - Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of...

08/14/14 - 20140227255 - Combination therapy of anti-her3 antibodies
The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies....

08/14/14 - 20140227256 - Predictive biomarker for cancer treatment with adcc-enhanced antibodies
The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody....

08/14/14 - 20140227257 - Monoclonal antibodies that neutralize anthrax protective antigen (pa) toxin
The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides...

08/14/14 - 20140227258 - Humanized anti-cmet antagonists
The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies....

08/14/14 - 20140227259 - Modified proteins and peptides
The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody...

08/14/14 - 20140227260 - Aminopyrimidine inhibitors of tyrosine kinase
The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof....

08/14/14 - 20140227261 - Use of omega fatty acids for treating disease
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof, are provided for use in the treatment and/or prophylaxis of a condition selected from macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined...

08/07/14 - 20140219999 - Treatment of colon cancer using complement inhibitors
Methods for treating, preventing or delaying onset of polyp formation and subsequent colon cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumorigenic or pre-tumorigenic tissue....

08/07/14 - 20140220000 - Mhc engagement and clip modulation for the treatment of disease
The invention relates to methods for treating disorders by targeting CLIP molecules and MHC. The methods are useful for treating, inhibiting the development of, or otherwise dealing with diseases such as HIV, blood vessel proliferative disorder, cancer and fibrosis....

08/07/14 - 20140220001 - Methods and monitoring of treatment with a dll4 antagonist
Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity....

08/07/14 - 20140220002 - Combination therapies employing gitr binding molecules
The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents....

08/07/14 - 20140220003 - Therapeutic method for mesothelioma
The present invention relates to a therapeutic method and a diagnostic method using an antibody that binds to a ganglioside GM2 antigen, and a therapeutic agent and a diagnostic agent comprising as an active ingredient an antibody that binds to a ganglioside GM2 antigen. According to the present invention, the...

08/07/14 - 20140220004 - Compositions and methods for treating pain
Provided herein are compositions containing an antibody or antigen-binding antibody fragment that specifically binds to metallothionein 2 (MT2) protein, and compositions containing an agent that binds to or neutralizes a function of MT2 protein and/or an oligonucleotide that decreases the expression of MT2 mRNA in a mammalian cell, and optionally,...

08/07/14 - 20140220005 - N-cadherin: target for cancer diagnosis and therapy
The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers....

08/07/14 - 20140220006 - Lung cancer biomarkers
The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with...

08/07/14 - 20140220007 - Lupus biomarkers
The present invention relates to methods of diagnosing lupus in a patient, as well as methods of monitoring the progression of lupus and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic...

08/07/14 - 20140220008 - Humanized anti-cd4 antibody with immunosuppressive properties
A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions....

08/07/14 - 20140220009 - Compositions and methods for treating cocaine-related disorders
A method of treating a cocaine-related disorder in an individual is provided, the method including administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In a specific embodiment, the antibody is a monoclonal antibody comprising a...

08/07/14 - 20140220010 - Variants of humanized immunomodulatory monoclonal antibodies
The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized...

07/31/14 - 20140212409 - Method for increasing deposition of complement c3b on bacterial surface and phagocytosis by phagocyte and a therapeutic method and a therapeutic agent for bacterial infections
The present invention relates to a method for increasing deposition of complement C3b on the bacterial surface and phagocytosis by phagocytes, a therapeutic method and a therapeutic agent for bacterial infections, using an antibody binding to a molecule on the bacterial surface, in which the antibody is modified by substituting...

07/31/14 - 20140212410 - Co-administration of eribulin and farletuzumab for the treatment of breast cancer
A method for transmission network control, the transmission network being configured for use in providing electricity from a generator to an end user, the method including receiving a sensitivity parameter, identifying a switchable set of switches within the transmission network using the sensitivity parameter, determining a candidate switch from the...

07/31/14 - 20140212411 - Methods of treatment using anti-erbb antibody-maytansinoid conjugates
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates....

07/31/14 - 20140212412 - Use of il-33 antagonists to treat fibrotic disease
Methods for treating fibrotic disease, such as idiopathic pulmonary fibrosis and scleroderma, with antagonists of IL-33 are disclosed....

07/31/14 - 20140212413 - Methods of treating tnf-alpha-mediated diseases using chimeric tnf-alpha antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of...

07/31/14 - 20140212414 - Combination therapy using p53 activator and c-met inhibitor
A method of preventing and/or treating a cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof....

07/31/14 - 20140212415 - Hypoxia-related gene signatures for cancer classification
Biomarkers, particularly hypoxia-related genes, and methods using the biomarkers for molecular classification of disease are provided....

07/31/14 - 20140212416 - Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long HCDR3s from non-human vertebrates and cells. The present invention is also directed to the provision of novel V, D and J pairings...

07/31/14 - 20140212417 - Prolonged inhibition of interleukin-6 mediated signaling
Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that...

07/24/14 - 20140205593 - Monovalent antibody fragments useful as therapeutics
The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment....

07/24/14 - 20140205594 - Treatment of cancer
Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101....

07/24/14 - 20140205595 - Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the...

07/24/14 - 20140205596 - Organic compounds
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer....

07/24/14 - 20140205597 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA...

07/24/14 - 20140205598 - Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to...